Article
A single missense mutant of Smad3 inhibits activation of both Smad2 and Smad3, and has a dominant negative effect on TGF-beta signals.
FEBS letters - 3 Jul 1998
Goto D, Yagi K, Inoue H, Iwamoto I, Kawabata M, Miyazono K, Kato M
Abstract excerpt
A missense mutation of Smad2 identified in cancer cells was reconstructed on the corresponding residue of Smad3. This mutant, Smad3D407E, was not phosphorylated by the constitutively active form of type I receptor for transforming growth factor-beta (TGF-beta), and inhibited the phosphorylation of co-expressed wild-type Smad2 and Smad3. This mutant also had a dominant negative effect on the growth inhibition of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.